At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 426 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Randomised, Placebo-controlled Study Comparing the Efficacy and Safety of Two Fixed Dosages of a Novel Antidepressant Compound to That of Placebo in Patients With Major Depressive Disorder
In Brief
A Phase 2 clinical trial evaluating Placebo, Vortioxetine (Lu AA21004), and 1 other intervention for Major Depressive Disorder. Completed, enrolled 426 participants.
Detailed Summary
The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
Primary CompletionAug 2007
Study CompletionSep 2007
First PostedFeb 2009
TodayJul 2026
First PostedFeb 9, 2009
Enrollment StartAug 1, 2006
Primary CompletionAug 1, 2007
Study CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.4 years ago
Interventions
Placebodrug
capsules, daily, orally
Vortioxetine (Lu AA21004)drug
encapsulated tablets, daily, orally
Venlafaxine XLdrug
capsules, daily, orally